Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • lean NAFLD
Lean MASLD Is Not Benign: Higher Liver Events and Mortality in Normal-BMI Patients Across Three Large Cohorts
Posted inGastroenterology Internal Medicine news

Lean MASLD Is Not Benign: Higher Liver Events and Mortality in Normal-BMI Patients Across Three Large Cohorts

Posted by MedXY By MedXY 11/07/2025
A pooled analysis of three population cohorts shows lean MASLD carries higher risks of liver-related events and all-cause and liver-related mortality despite lower cardiovascular event risk compared with non-lean MASLD.
Read More
  • Beyond Nodal Status: A New Risk Score Predicts Recurrence in Lymph Node-Negative Pancreatic Neuroendocrine Tumors
  • Breaking the Data Silos: Why Sharing Clinical Trial Biospecimens Is Non-Negotiable for Cancer Care
  • Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC
  • Preoperative Cardiovascular Risk Does Not Dictate RAS Inhibitor Management: Insights from the STOP-or-NOT Trial
  • Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial screening SGLT2 inhibitors targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in